Table 2. Multivariate analysis for hand grip strength and SMI in patients with Sjogren's syndrome

	Unstandardized Coefficients		95% Confidence Interval for B		Standardized Coefficients	
	B	Std. Error	Lower	Upper	Beta	p-value
Hand grip strength						
Constant	24,492	1,695	21,071	27,914	—	<0.001
ESSPRI pain	-0,707	0,282	-1,276	-0,139	-0,361	0,016
SMI						
Constant	5,419	1,705	1,978	8,860	—	0,003
MNA	0,380	0,127	-1,276	-0,139	0,419	0,005

ESSPRI: EULAR Sjogren's Syndrome Patient Reported Index, SMI: Skeletal Muscle Index, MNA: Mini Nutritional Assessment

Conclusion: Risk of sarcopenia is increased in patients with SS. In the current study, it is shown that pain is related with sarcopenia. ESSPRI pain is a sign of continuing chronic inflammation in patients with SS. Malnutrition, which can indirectly related with SS, may also contribute to this process. Excessive pain may lead to decrease daily activities and nutritional status of patients with SS. Evaluating pain and patient's global disease activity may help physicians to find out patients with increased risk for sarcopenia. Controlling disease activity and pain and preventing malnutrition may reduce the risk for development of sarcopenia.

Acknowledgments : None to declare

Disclosure of Interests : None declared

DOI: 10.1136/annrheumdis-2020-eular.4918

AB0405

ABNORMAL BLOOD LIPID METABOLISM IN PREMENOPAUSAL FEMALE SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IS RELATED TO HYPERURICEMIA AND PROTEINURIA

H. Liu¹, J. Z. Lin², X. Cai³, J. D. MA², Y. Mo², M. Xie¹, L. Dai². ¹Panyu Central Hospital, Department of Rheumatology, Guangzhou, China; ²Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Department of Rheumatology, Guangzhou, China; ³Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology, Department of Rheumatology, Guangzhou, China

Background: 1. Hyperuricemia is often associated with abnormal lipid metabolism. We reported premenopausal female systemic lupus erythematosus (SLE) patients had elevated blood UA levels^[1]. Do these patients also have hyperlipidemia?

2. Estrogen has certain effect on blood lipid metabolism, whether the blood lipid levels of premenopausal female SLE patients who have the background of hyperestrogen function are affected by estrogen and its receptors?

Objectives: To investigate the relationships between blood lipids and serum UA level, estrogen receptors (ERs) as well as ER antibodies in premenopausal female SLE patients.

Methods: 123 premenopausal female SLE patients (SLE group) were divided into normal CH group (n=93) and high CH group (n=30, CH>5.17mmol/l), and 40 healthy premenopausal females served as the control group. The blood lipid levels of the SLE group and the control group were compared, and the blood levels of lipid, UA, estrogen, ERs and ER antibodies were compared between the two SLE subgroups. Linear regression was used to analyze the influencing factors of blood CH.

Results:

1. In SLE group, the blood level of TG was significantly higher than that of the control group (1.67±1.10 vs. 0.87±0.47, P<0.001), while the levels of blood CH, LDL, HDL were comparable to the control group (all with P>0.05).
2. The mean blood CH level of the SLE patients with hyperuricemia was 5.57 ± 2.44mmol/l, which was significantly higher than that of patients with normal UA level (3.98 ± 1.30mmol/l, P<0.001).
3. The serum UA, CRE, CH, TG, LDL, and 24-hour urinary protein quantification (24h UPRO) in the high CH SLE subgroup were significantly higher than those in the normal CH SLE subgroup (all with P<0.05). There were no significant differences in serum estrogen, ERs and ER antibodies between the two subgroups, Table 1.
4. Linear regression showed that serum UA level and 24h UPRO were the dangerous effects of elevated blood CH in the premenopausal female SLE patients, Table 2.

Conclusion: Compared with healthy female of the same age range, the premenopausal female SLE patients are more likely to have abnormal lipid metabolism, which is related to kidney damage and abnormal UA metabolism.

References:

- [1] Haijun Liu, Xiaoyan Cai, Lie Dai, et al. Elevated uric acid levels in premenopausal female systemic lupus erythematosus patients: association with potential or existing renal damage. Eur J Inflamm, 2018, 16: 1-6.

Table 1. Some clinical indicators, estrogen, ERs and ER antibodies in the premenopausal female SLE patients

	High CH group (n=30)	Normal CH group (n=93)	P
Age(years)	31.40±7.40	28.12±7.23	0.039
UA(μmol/l)	433.40±192.90	310.10±129.57	0.002
CRE(μmol/l)	112.07±87.09	72.81±91.96	0.039
CH(mmol/l)	7.07±2.05	3.72±0.93	<0.001
TG(mmol/l)	2.27±1.57	1.48±0.84	0.013
LDL(mmol/l)	4.48±1.46	2.29±0.67	<0.001
HDL(mmol/l)	1.02±0.72	1.97±0.43	0.721
Estrogen(pg/ml)	73.53±47.74	69.42±55.48	0.717
ERα(pg/ml)	45.94±31.06	43.34±31.05	0.684
ERβ(pg/ml)	16.65±28.67	13.70±25.09	0.589
Anti-ERα(ng/ml)	59.75±33.87	55.16±31.34	0.496
Anti-ERβ(ng/ml)	89.73±49.03	71.73±41.74	0.052
24h UPRO(g/24h)	2.82±3.82	0.39±0.56	0.002
Positive UBLD(%)	20(66.67)	31(33.33)	0.01
SLEDAI	13.18±4.23	7.39±6.18	0.025

ER, estrogen receptor; 24h UPRO, 24-hour urinary protein quantification; UBLD, urinary blood.

Table 2. Relationships between blood CH level and clinical indicators in the premenopausal female SLE patients

Variable	Unstandardized Coefficients		Standardized Coefficients	t	P	95%CI
	B	SEM				
24h UPRO	0.353	0.072	0.400	4.932	<0.001	0.211-0.495
UA	0.003	0.001	0.249	3.058	0.003	0.001-0.005
Constant	3.146	0.359		8.754	<0.001	2.434-3.857

UA, uric acid; 24h UPRO, 24-hour urinary protein quantification.

Disclosure of Interests : None declared

DOI: 10.1136/annrheumdis-2020-eular.2696

AB0406

HUMAN PAPILLOMA VIRUS (HPV) VACCINATION SAFETY IN SYSTEMIC LUPUS ERYTHEMATOSUS COHORT - PORTUGUESE UNIVERSITY HOSPITAL SINGLE-CENTER COHORT STUDY

J. Sousa Morais¹, D. G. Oliveira², B. Faria^{3,4}, A. Almeida³, M. Brandão^{3,4}, A. Marinho^{3,4}, I. Almeida^{3,4}, F. Farinha³, C. Vasconcelos^{3,4}. ¹Serviço de Medicina, Hospital de São Marcos, Braga, Portugal; ²Serviço de Medicina, Porto, Portugal; ³Unidade de Imunologia Clínica, Porto, Portugal; ⁴Abel Salazar Biomedical Sciences Institute - University of Porto, UMIB, Porto, Portugal

Background: Cervical cancer is a potentially preventable consequence of Human Papillomavirus (HPV). HPV vaccination is recommended in most countries for all young women, preferentially before sexual activity begins. In Portugal, HPV vaccination is available in either bivalent (genotypes 6, 18) or tetravalent (6, 11, 16 e 18) vaccines. Both have aluminum as an adjuvant, a substance arguably capable of inducing inflammatory adjuvant syndromes. Systemic Lupus Erythematosus (SLE) mostly affects women of childbearing age, the very target population for HPV vaccination. There are conflicting reports in the literature regarding both the efficacy and safety of this vaccine in SLE patients. This question is particularly pressing as HPV infection prevalence seems to be increased in SLE patients.

Objectives: To analyze the safety of HPV vaccination in a SLE patient cohort followed at a university hospital.

Methods: Retrospective single-center (35 year long, 436 SLE patient cohort) review of all female SLE patients' local and online national records on HPV vaccination and cervical cancer screening. Data on activity (using SLEDAI-2K scoring) and concomitant drug use were reviewed for the two years before and after vaccination date.

Results: Of the 463 SLE patients, 420 were women (91%), of which 322 had clinical information about yes/no HPV vaccination. Twenty-seven of the patients (8%) had one of HPV vaccines, but only 13 (4%) had full information on activity before and after vaccination. Mean current age was 33,8 years and a minimum of 8,4 years of follow-up after HPV vaccination. Twenty-three (85%) were vaccinated with the tetravalent vaccine. Pre-vaccination mean SLEDAI score of was 5.9: due to arthritis (n= 5; 38,5%), low complement